Investor profile
OrbiMed has backed 13 European tech companies across 14 funding rounds between 2015 and 2025, joining rounds totalling €1.1B. Most active in Healthtech and AI. Data as of 6 Aug 2026.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Verdiva Bio | UK | 1 | €399M |
| Amolyt Pharma | France | 1 | €129M |
| Vectivbio | Switzerland | 1 | €127M |
| Charm Therapeutics | UK | 2 | €116M |
| Galecto Biotech | Denmark |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Verdiva Bio | Series A | €399M | 2025-01 |
| Amolyt Pharma | Series C | €129M | 2023-01 |
| Vectivbio | Other | €127M | 2022-10 |
| Galecto Biotech |
| 1 |
| €79M |
| ProVerum | Ireland | 1 | €68M |
| ObsEva | Switzerland | 1 | €54M |
| MinervaX | Denmark | 1 | €54M |
| BiomX | Israel | 1 | €22M |
| Azura Ophthalmics | Israel | 1 | €17M |
| blue inductive | Germany | 1 | €6.0M |
| MobileODT | Israel | 1 | €3.4M |
| Nucleix | Israel | 1 | €2.7M |
| Series C |
| €79M |
| 2018-10 |
| Charm Therapeutics | Series B | €69M | 2025-09 |
| ProVerum | Series B | €68M | 2025-08 |
| ObsEva | Series B | €54M | 2015-11 |
| MinervaX | Other | €54M | 2023-10 |
| Charm Therapeutics | Series A | €47M | 2022-06 |
| BiomX | Series A | €22M | 2017-05 |
